A Cordis IVC filter lawsuit may be an option for patients who have experienced complications after having an inferior vena cava (IVC) filter procedure. Patients with a high risk of developing pulmonary thromboembolism, a complication associated with deep vein thrombosis, may choose to have an IVC filter implanted to block the path of clots within the IVC. Despite the effectiveness of some IVC filters, two filter brands have been associated with frequent filter fracture and risk of implanting backwards. Affected patients and their families may be able to file a lawsuit and recover compensation with the help of a Cordis IVC filter lawsuit attorney.
If you or a loved one suffered complications after a Cordis IVC filter procedure involving the Cordis TrapEase filter or the Cordis OptEase filter, contact Attorney Group to learn more. We offer free, confidential, no obligation consultations. We can help answer your questions and inform you of your options. If you choose to pursue a claim, we can connect you with an affiliated IVC filter attorney who can assist you throughout the legal process.
What is an IVC Filter?
An IVC filter is a small, cone-shaped medical device that is implanted into the inferior vena cava, a large vein that carries deoxygenated blood from the lower part of the body to the heart and lungs, to prevent pulmonary emboli from occurring. The device works by catching blood clots, known as emboli, that have become loose from one of the deep veins in the lower extremities. Without an IVC filter in place, there is the potential for an embolism to block the pulmonary artery.
People who experience deep vein thrombosis (DVT) or pulmonary embolism even when treated with anticoagulants, people who cannot take anticoagulants due to other conditions, people who develop significant bleeding complications from anticoagulants, or people who develop large clots in the IVC veins or iliac veins are possible candidates for treatment with an IVC filter.
IVC Filter Risks
Since 2005, the U.S. Food and Drug Administration (FDA) has received over 900 device adverse event reports involving IVC filters.
According to the FDA, risks commonly reported include:
- Device migration
- Detachment of device components
- Perforation of the IVC
- Filter fracture
In their initial communication, the FDA reported that such events may be related to a retrievable filter remaining in the body long after the risk of pulmonary embolism has subsided. Most IVC filters are intended for short-term use, however, some remain in the patient’s vein for long periods of time, potentially leading to serious complications.
In an update issued by the FDA in 2014, the agency made further recommendations regarding the implantation, monitoring and retrieval of the small, cage-like devices. Physicians have been advised to consider removing the filter once the risk of pulmonary embolism has diminished. Using publicly available data in medical literature, the FDA’s decision analysis (published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders in 2013) determined that the risk/benefit profile begins to favor IVC filter removal between 29 and 54 days after implantation and once the risk of pulmonary embolism has passed.
Cordis TrapEase Filter Risks
According to an article published in the JAMA Internal Medicine, researchers determined that, despite the popularity of the devices, patients undergoing permanent Cordis TrapEase filter insertion are at an extremely high risk of strut fractures as early as two to three years after the filter’s placement. While life-threatening events were not recorded in the study, the article states that several reports have previously warned of potentially fatal complications, including cardiac tamponade or ventricular tachycardia. As a result, researchers warn that permanent IVC filters, such as the Cordis TrapEase filter, should be used with caution and followed closely.
Cordis OptEase Filter Risks
The Cordis OptEase filter is a type of IVC filter designed to be retrieved when the patient no longer needs the device. The device has a recommended time of removal of up to 23 days after insertion. In a study published in 2005, researchers sought to determine the safety, feasibility and reaction of the vena cava when removing the devices at different time intervals. Based on the results of the study, Cordis OptEase filters can be successfully retrieved up to 14 days after insertion. At long time intervals, strut protrusion through the vena cava’s wall prohibited successful and safe removal of the device.
Likewise, the FDA issued recall information regarding the Cordis OptEase filter. The devices were recalled, as the FDA requested a labeling correction to provide further clarification and to avoid the likelihood that the devices would be implanted backwards.
How a Cordis IVC Filter Lawsuit Attorney Can Help
Medical device makers have a duty to provide safe products. If there are risks of harm associated with their devices, they also must provide adequate warnings. If a device maker fails to fulfill this duty, it could be held liable in lawsuits for injuries that may result.
People injured by a defective Cordis IVC filter may be eligible to recover money for:
- Medical Expenses
- Lost Wages
- Pain and Suffering
The families of those killed may be eligible to recover money for funeral expenses and the pain that comes with losing a loved one.
For more information, contact Attorney Group. After you contact us, an attorney will follow up to answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.
Please note that the law limits the time you have to pursue a claim or file a lawsuit for an injury. If you think you have a case, you should not delay taking action.
